Acute Gastrointestinal Injury in Pediatrics (AGI)
Acute Gastrointestinal Injury in Critically Ill Children in Pediatric Intensive Care Unit of Cipto Mangunkusumo Hospital
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Antonius H Pudjiadi, MD, PhD
- Phone Number: +628164812035
- Email: ahpudjiadi@gmail.com
Study Contact Backup
- Name: Gryselda Hanafi, MD
- Phone Number: 00 087170113134
- Email: gryseldahanafi@gmail.com
Study Locations
-
-
DKI Jakarta
-
Jakarta Pusat, DKI Jakarta, Indonesia, 10430
- Recruiting
- Cipto Mangunkusumo Hospital
-
Contact:
- Antonius Pudjiadi, MD, PhD
- Phone Number: +621500135
- Email: info@rscm.co.id
-
Sub-Investigator:
- Fatima Safira Alatas, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- critically ill pediatric patients receiving care at the PICU
- presence of AGI (any degree)
Exclusion Criteria:
- patients who's body weight cannot be measured
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PELOD-2 score
Time Frame: time of AGI diagnosis, day-1 PELOD-2 score
|
The Pediatric Logistic Organ Dysfunction (PELOD)-2 score is used to predict mortality and assess organ dysfunction.
It consist of 10 components, assessing 5 organ dysfunction.
The minimum score of PELOD-2 is 0 and the maximum score is 33.
With the increasing organ dysfunction, the probability of death also increases.
|
time of AGI diagnosis, day-1 PELOD-2 score
|
|
mortality
Time Frame: days from PICU admission date up to 28 days follow-up
|
PICU mortality
|
days from PICU admission date up to 28 days follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Antonius H Pudjiadi, MD, PhD, Indonesia University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19-04-0471
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.